Contributions
Abstract: PB2005
Type: Publication Only
Background
Global gains in treatment of MM using auto-PBHSCT testify to heterogeneity of long-term outcomes of transplantation - different term of the achievement and duration of complete remission, progression-free survival (PFS), overall survival (OS). These facts determine individual approach to the application of PBHSCT.
Aims
Finding molecular genetic criteria of predicting the effectiveness of autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT) for improving of algorithm of multiple myeloma (MM) patients cure at various stages of treatment
Methods
The study involved 61 patients with MM with relapse and primary therapy resistant patients. Molecular cytogenetic, immunogenetic, hematological and statistical methods were used.
Results
Since appearance of genetic abnormalities in the malignant plasma cells is one of the pathogenic mechanisms of the disease, genetic support of patients is essential. It was determined that the carriage of the allele HLA-DQB1*03: 02 in MM patients is associated with a high risk of high-dose chemotherapy resistance (F = 4,83, p = 0,028; OR = 1,75, p = 0.038), and achieving remission after auto-PBSCT is associated with carriage of haplotype HLA-C *06 - HLA-DQA1*01: 01 (F = 4,87, p = 0,028; OR = 7,34, p = 0,05). Abnormalities of chromosomes 4, 11, 13, 14, 16 and 17 were determined in 35 of 61 (57%) MM patients with complicated disease course and minimal therapy response. Significant alterations were revealed in the presence of two or more abnormal clones (23 patients (37,7%), Ro Spirman = 0,42, p <0,05), deletion of chromosome 17 (17 patients (27,9%), Ro Spirman = 0,41, p <0,05), deletion/monosomy of chromosome 13 (10 of 15 patients surveyed, Ro Spirman = 0,33, p <0,05), the translocation t(4;14) (4 patients (6,6%), Ro Spirman = 0,50, p <0,02).
Conclusion
The results indicate the necessity of introducing the molecular genetic support into protocol of examination MM patients on various stages of treatment with auto-PBHSCT.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Multiple Myeloma, HSCT, HLA, Cytogenetics
Abstract: PB2005
Type: Publication Only
Background
Global gains in treatment of MM using auto-PBHSCT testify to heterogeneity of long-term outcomes of transplantation - different term of the achievement and duration of complete remission, progression-free survival (PFS), overall survival (OS). These facts determine individual approach to the application of PBHSCT.
Aims
Finding molecular genetic criteria of predicting the effectiveness of autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT) for improving of algorithm of multiple myeloma (MM) patients cure at various stages of treatment
Methods
The study involved 61 patients with MM with relapse and primary therapy resistant patients. Molecular cytogenetic, immunogenetic, hematological and statistical methods were used.
Results
Since appearance of genetic abnormalities in the malignant plasma cells is one of the pathogenic mechanisms of the disease, genetic support of patients is essential. It was determined that the carriage of the allele HLA-DQB1*03: 02 in MM patients is associated with a high risk of high-dose chemotherapy resistance (F = 4,83, p = 0,028; OR = 1,75, p = 0.038), and achieving remission after auto-PBSCT is associated with carriage of haplotype HLA-C *06 - HLA-DQA1*01: 01 (F = 4,87, p = 0,028; OR = 7,34, p = 0,05). Abnormalities of chromosomes 4, 11, 13, 14, 16 and 17 were determined in 35 of 61 (57%) MM patients with complicated disease course and minimal therapy response. Significant alterations were revealed in the presence of two or more abnormal clones (23 patients (37,7%), Ro Spirman = 0,42, p <0,05), deletion of chromosome 17 (17 patients (27,9%), Ro Spirman = 0,41, p <0,05), deletion/monosomy of chromosome 13 (10 of 15 patients surveyed, Ro Spirman = 0,33, p <0,05), the translocation t(4;14) (4 patients (6,6%), Ro Spirman = 0,50, p <0,02).
Conclusion
The results indicate the necessity of introducing the molecular genetic support into protocol of examination MM patients on various stages of treatment with auto-PBHSCT.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Multiple Myeloma, HSCT, HLA, Cytogenetics